Your browser doesn't support javascript.
loading
History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial.
Lewis, Cora E; Bantle, John P; Bertoni, Alain G; Blackburn, George; Brancati, Frederick L; Bray, George A; Cheskin, Lawrence J; Curtis, Jeffrey M; Egan, Caitlin; Evans, Mary; Foreyt, John P; Ghazarian, Siran; Barone Gibbs, Bethany; Glasser, Stephen P; W Gregg, Edward; Hazuda, Helen P; Hesson, Louise; Hill, James O; Horton, Edward S; Hubbard, Van S; Jakicic, John M; Jeffery, Robert W; Johnson, Karen C; Kahn, Steven E; Kitabchi, Abbas E; Kitzman, Dalane; Knowler, William C; Lipkin, Edward; Michaels, Sara; Montez, Maria G; Nathan, David M; Nyenwe, Ebenezer; Patricio, Jennifer; Peters, Anne; Pi-Sunyer, Xavier; Pownall, Henry; Reboussin, David M; Ryan, Donna H; Wadden, Thomas A; Wagenknecht, Lynne E; Wyatt, Holly; Wing, Rena R; Yanovski, Susan Z.
Afiliação
  • Lewis CE; University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Bantle JP; University of Minnesota, Minneapolis, Minnesota, USA.
  • Bertoni AG; Wake Forest University, Winston-Salem, North Carolina, USA.
  • Blackburn G; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Brancati FL; Johns Hopkins University, Baltimore, Maryland, USA.
  • Bray GA; Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
  • Cheskin LJ; Johns Hopkins University, Baltimore, Maryland, USA.
  • Curtis JM; Southwestern American Indian Center, National Institute of Diabetes and Digestive and Kidney Diseases and St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
  • Egan C; The Miriam Hospital, Brown Medical School, Providence, Rhode Island, USA.
  • Evans M; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
  • Foreyt JP; Baylor College of Medicine, Houston, Texas, USA.
  • Ghazarian S; University of Southern California, Los Angeles, California, USA.
  • Barone Gibbs B; University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Glasser SP; University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • W Gregg E; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Hazuda HP; University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
  • Hesson L; University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Hill JO; University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Horton ES; Joslin Diabetes Center, Boston, Massachusetts, USA.
  • Hubbard VS; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
  • Jakicic JM; University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Jeffery RW; University of Minnesota, Minneapolis, Minnesota, USA.
  • Johnson KC; The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Kahn SE; US Department of Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA.
  • Kitabchi AE; The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Kitzman D; Wake Forest University, Winston-Salem, North Carolina, USA.
  • Knowler WC; Southwestern American Indian Center, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.
  • Lipkin E; US Department of Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA.
  • Michaels S; Southwestern American Indian Center, Shiprock, New Mexico, USA.
  • Montez MG; University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
  • Nathan DM; Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Nyenwe E; The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Patricio J; St. Luke's Roosevelt Hospital Center, Columbia University, New York, New York, USA.
  • Peters A; University of Southern California, Los Angeles, California, USA.
  • Pi-Sunyer X; St. Luke's Roosevelt Hospital Center, Columbia University, New York, New York, USA.
  • Pownall H; Baylor College of Medicine, Houston, Texas, USA.
  • Reboussin DM; Wake Forest University, Winston-Salem, North Carolina, USA.
  • Ryan DH; Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
  • Wadden TA; University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Wagenknecht LE; Wake Forest University, Winston-Salem, North Carolina, USA.
  • Wyatt H; University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Wing RR; The Miriam Hospital, Brown Medical School, Providence, Rhode Island, USA.
  • Yanovski SZ; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
Obesity (Silver Spring) ; 28(2): 247-258, 2020 02.
Article em En | MEDLINE | ID: mdl-31898874
OBJECTIVE: To examine the effects of an intensive lifestyle intervention (ILI) on cardiovascular disease (CVD), the Action for Health in Diabetes (Look AHEAD) trial randomized 5,145 participants with type 2 diabetes and overweight/obesity to a ILI or diabetes support and education. Although the primary outcome did not differ between the groups, there was suggestive evidence of heterogeneity for prespecified baseline CVD history subgroups (interaction P = 0.063). Event rates were higher in the ILI group among those with a CVD history (hazard ratio 1.13 [95% CI: 0.90-1.41]) and lower among those without CVD (hazard ratio 0.86 [95% CI: 0.72-1.02]). METHODS: This study conducted post hoc analyses of the rates of the primary composite outcome and components, adjudicated cardiovascular death, nonfatal myocardial infarction (MI), stroke, and hospitalization for angina, as well as three secondary composite cardiovascular outcomes. RESULTS: Interaction P values for the primary and two secondary composites were similar (0.060-0.064). Of components, the interaction was significant for nonfatal MI (P = 0.035). This interaction was not due to confounding by baseline variables, different intervention responses for weight loss and physical fitness, or hypoglycemic events. In those with a CVD history, statin use was high and similar by group. In those without a CVD history, low-density lipoprotein cholesterol levels were higher (P = 0.003) and statin use was lower (P ≤ 0.001) in the ILI group. CONCLUSIONS: Intervention response heterogeneity was significant for nonfatal MI. Response heterogeneity may need consideration in a CVD-outcome trial design.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Estilo de Vida Tipo de estudo: Clinical_trials Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Estilo de Vida Tipo de estudo: Clinical_trials Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article